Personal tools

Coexpression cluster:C422: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
(Created page with "{{Coexpression_clusters |full_id=C422_mesenchymal_Smooth_Fibroblast_papillary_Endothelial_fibrous_osteosarcoma |id=C422 }}")
 
No edit summary
Line 2: Line 2:
|full_id=C422_mesenchymal_Smooth_Fibroblast_papillary_Endothelial_fibrous_osteosarcoma
|full_id=C422_mesenchymal_Smooth_Fibroblast_papillary_Endothelial_fibrous_osteosarcoma
|id=C422
|id=C422
|ontology_enrichment_celltype=CL:0000055!1.08e-24!180;CL:0000220!1.82e-24!246;CL:0002321!7.63e-24!248;CL:0000222!1.92e-18!119;CL:0002371!6.51e-17!591;CL:0000187!1.28e-15!54;CL:0000680!1.55e-15!57;CL:0000056!1.55e-15!57;CL:0000355!1.55e-15!57;CL:0000183!2.18e-14!59;CL:0000144!2.31e-14!625;CL:0000359!2.71e-14!32;CL:0000192!4.11e-14!42;CL:0000514!4.11e-14!42;CL:0000548!1.29e-13!679;CL:0000004!1.29e-13!679;CL:0000255!1.29e-13!679;CL:0000393!1.64e-13!60;CL:0000211!1.64e-13!60;CL:0000012!7.16e-13!682;CL:0000057!5.29e-12!75;CL:0002139!3.68e-11!24;CL:0000115!1.12e-08!35;CL:0000071!1.73e-08!18;CL:0002546!1.73e-08!18;CL:0002494!6.85e-08!16;CL:0002620!1.11e-07!23;CL:0002539!1.27e-07!10
|ontology_enrichment_disease=DOID:2394!4.63e-07!14
|ontology_enrichment_uberon=UBERON:0004872!6.09e-25!84;UBERON:0001637!6.28e-25!42;UBERON:0003509!6.28e-25!42;UBERON:0004572!6.28e-25!42;UBERON:0000055!9.02e-23!69;UBERON:0001981!9.73e-23!60;UBERON:0007500!9.73e-23!60;UBERON:0004537!9.73e-23!60;UBERON:0006965!9.73e-23!60;UBERON:0003914!6.34e-20!118;UBERON:0002049!6.89e-20!79;UBERON:0007798!6.89e-20!79;UBERON:0004573!9.24e-20!33;UBERON:0004571!9.24e-20!33;UBERON:0000914!2.29e-18!83;UBERON:0002329!2.29e-18!83;UBERON:0003077!2.29e-18!83;UBERON:0003059!2.29e-18!83;UBERON:0007282!2.29e-18!83;UBERON:0009618!2.29e-18!83;UBERON:0007285!2.29e-18!83;UBERON:0000490!1.44e-17!138;UBERON:0000486!9.98e-17!82;UBERON:0004290!1.05e-16!70;UBERON:0004535!1.65e-16!110;UBERON:0005256!5.04e-16!143;UBERON:0001009!1.53e-15!113;UBERON:0000467!3.08e-14!625;UBERON:0000480!5.44e-14!626;UBERON:0003102!3.13e-13!95;UBERON:0000468!4.45e-13!659;UBERON:0001134!4.97e-13!61;UBERON:0002036!4.97e-13!61;UBERON:0003082!4.97e-13!61;UBERON:0002385!6.84e-13!63;UBERON:0001015!6.84e-13!63;UBERON:0000383!6.84e-13!63;UBERON:0000947!1.23e-12!21;UBERON:0010191!1.23e-12!21;UBERON:0000926!5.52e-12!448;UBERON:0004120!5.52e-12!448;UBERON:0006603!5.52e-12!448;UBERON:0002100!2.40e-11!216;UBERON:0002199!1.77e-10!45;UBERON:0002416!1.77e-10!45;UBERON:0000923!1.82e-09!604;UBERON:0005291!1.82e-09!604;UBERON:0006598!1.82e-09!604;UBERON:0002532!1.82e-09!604;UBERON:0002097!2.54e-09!40;UBERON:0002050!2.87e-09!605;UBERON:0005423!2.87e-09!605;UBERON:0000922!3.08e-09!612;UBERON:0000119!4.79e-09!312;UBERON:0003104!5.69e-09!238;UBERON:0009142!5.69e-09!238;UBERON:0000483!7.60e-09!309;UBERON:0001986!1.73e-08!18;UBERON:0004638!1.73e-08!18;UBERON:0004852!1.73e-08!18;UBERON:0000487!2.08e-08!22;UBERON:0001135!1.14e-07!15;UBERON:0004237!1.27e-07!10;UBERON:0004695!1.27e-07!10;UBERON:0002111!1.27e-07!10;UBERON:0004178!1.27e-07!10;UBERON:0006914!1.36e-07!25;UBERON:0004111!1.79e-07!241;UBERON:0000475!4.04e-07!365;UBERON:0000481!5.66e-07!347
}}
}}

Revision as of 14:46, 21 May 2012


Full id: C422_mesenchymal_Smooth_Fibroblast_papillary_Endothelial_fibrous_osteosarcoma



Phase1 CAGE Peaks

Hg19::chr11:102661061..102661115,-p@chr11:102661061..102661115
-
Hg19::chr11:102661460..102661475,-p@chr11:102661460..102661475
-
Hg19::chr11:102661517..102661541,-p@chr11:102661517..102661541
-
Hg19::chr11:102662162..102662217,-p@chr11:102662162..102662217
-
Hg19::chr11:102662218..102662229,-p@chr11:102662218..102662229
-
Hg19::chr11:102663376..102663430,-p@chr11:102663376..102663430
-
Hg19::chr11:102663449..102663467,-p@chr11:102663449..102663467
-
Hg19::chr11:102665915..102665927,+p@chr11:102665915..102665927
+
Hg19::chr11:102665942..102665954,-p@chr11:102665942..102665954
-
Hg19::chr11:102665984..102666003,-p@chr11:102665984..102666003
-
Hg19::chr11:102666252..102666270,-p2@MMP1
Hg19::chr11:102667434..102667447,-p@chr11:102667434..102667447
-
Hg19::chr11:102667477..102667490,-p@chr11:102667477..102667490
-
Hg19::chr11:102667504..102667527,-p@chr11:102667504..102667527
-
Hg19::chr11:102668016..102668028,-p5@MMP1
Hg19::chr11:102668074..102668126,-p3@MMP1
Hg19::chr11:102668148..102668159,+p@chr11:102668148..102668159
+
Hg19::chr11:102668160..102668174,+p@chr11:102668160..102668174
+
Hg19::chr11:102668166..102668181,-p10@MMP1
Hg19::chr11:102668178..102668206,+p@chr11:102668178..102668206
+
Hg19::chr11:102668185..102668198,-p12@MMP1
Hg19::chr11:102668200..102668228,-p4@MMP1
Hg19::chr11:102668234..102668245,-p11@MMP1
Hg19::chr11:102668879..102668898,-p1@MMP1


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data


No GOStat results

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>


Uber Anatomy
Ontology termp-valuen
splanchnic layer of lateral plate mesoderm6.09e-2584
artery6.28e-2542
arterial blood vessel6.28e-2542
arterial system6.28e-2542
vessel9.02e-2369
blood vessel9.73e-2360
epithelial tube open at both ends9.73e-2360
blood vasculature9.73e-2360
vascular cord9.73e-2360
epithelial tube6.34e-20118
vasculature6.89e-2079
vascular system6.89e-2079
systemic artery9.24e-2033
systemic arterial system9.24e-2033
somite2.29e-1883
paraxial mesoderm2.29e-1883
presomitic mesoderm2.29e-1883
presumptive segmental plate2.29e-1883
trunk paraxial mesoderm2.29e-1883
presumptive paraxial mesoderm2.29e-1883
unilaminar epithelium1.44e-17138
multilaminar epithelium9.98e-1782
dermomyotome1.05e-1670
cardiovascular system1.65e-16110
trunk mesenchyme5.04e-16143
circulatory system1.53e-15113
anatomical system3.08e-14625
anatomical group5.44e-14626
surface structure3.13e-1395
multi-cellular organism4.45e-13659
skeletal muscle tissue4.97e-1361
striated muscle tissue4.97e-1361
myotome4.97e-1361
muscle tissue6.84e-1363
musculature6.84e-1363
musculature of body6.84e-1363
aorta1.23e-1221
aortic system1.23e-1221
mesoderm5.52e-12448
mesoderm-derived structure5.52e-12448
presumptive mesoderm5.52e-12448
trunk2.40e-11216
integument1.77e-1045
integumental system1.77e-1045
germ layer1.82e-09604
embryonic tissue1.82e-09604
presumptive structure1.82e-09604
epiblast (generic)1.82e-09604
skin of body2.54e-0940
embryonic structure2.87e-09605
developing anatomical structure2.87e-09605
embryo3.08e-09612
cell layer4.79e-09312
mesenchyme5.69e-09238
entire embryonic mesenchyme5.69e-09238
epithelium7.60e-09309
endothelium1.73e-0818
blood vessel endothelium1.73e-0818
cardiovascular system endothelium1.73e-0818
simple squamous epithelium2.08e-0822
smooth muscle tissue1.14e-0715
blood vessel smooth muscle1.27e-0710
arterial system smooth muscle1.27e-0710
artery smooth muscle tissue1.27e-0710
aorta smooth muscle tissue1.27e-0710
squamous epithelium1.36e-0725
anatomical conduit1.79e-07241
organism subdivision4.04e-07365
multi-tissue structure5.66e-07347
Disease
Ontology termp-valuen
ovarian cancer4.63e-0714


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data


No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data


This analysis result is provided for C0 - C305 clusters.